BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Argus Health

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Pleuromutilin derivatives as antimicrobials
Abstract:The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
Inventor(s): Berry; Valerie (Chester Springs, PA), Dabbs; Steven (Harlow, GB), Frydrych; Colin Henry (Sawbridgeworth, GB), Hunt; Eric (Great Dunmow, GB), Sanderson; Francis Dominic (Harlow, GB), Woodnutt; Gary (Chester Springs, PA)
Assignee: SmithKline Beecham p.l.c. (Brentford, GB)
Filing Date:Apr 27, 2000
Application Number:09/530,446
Claims:1. A compound of general formula (IA) or (IB): ##STR10##

in which:

each of n and m is independently 0, 1 or 2; and

X is selected from --O--, --S(O)--, --SO.sub.2 --, --CO.O--, --NH--, --CONH--, --NHCONH-- and a bond; or

n is 1 or 2 and m is 2 and X is --S--; and

R.sup.1 is vinyl or ethyl;

R.sup.2 is optionally substituted quinuclidinyl, azabicyclo[2.2.1]heptyl, azabicyclo[4,3,0]nonyl, azabicyclo[3.2.1]octyl, azabicyclo[3,3,0]octyl, azabicyclo[2.2.2]octyl, azabicyclo[3.2.1]octenyl, azabicyclo[3.3.1]nonyl or azabicyclo[4.4.0]decyl;

R.sup.3 is H or OH; or

the moiety R.sup.2 (CH.sub.2).sub.m X(CH.sub.2).sub.n CH.sub.2 COO at position 14 of (IA) or (IB) is replaced by R.sup.a R.sup.b C=CHCOO in which one of R.sup.a and R.sup.b is hydrogen and the other is R.sup.2 or R.sup.a and R.sup.b together form R.sup.2 ; or

a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 in which R.sup.2 is substituted by alkyl, alkyloxy, alkenyl or alkenyloxy, which are optionally further substituted by one or more groups selected from aryl, heterocyclyl, (C.sub.1-6)alkoxy, (C.sub.1-6)alkylthio, aryl(C.sub.1-6)alkoxy, aryl(C.sub.1-6)alkylthio, amino, mono- or di-(C.sub.1-6)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, amides of carboxy, ureido, carbamimidoyl (amidino), guanidino, alkyl-sulfonyl, amino-sulfonyl (C.sub.1-6)acyloxy, (C.sub.1-6)acylamino, azido, hydroxy, and halogen.

3. A compound according to claim 1 in which n is 0.

4. A compound according to claim 1 in which m is 0 or 1.

5. A compound according to claim 1 in which R.sup.2 is quinuclidinyl.

6. A compound according to claim 1 which has the formula (IA).

7. A compound according to claim 1 selected from:

mutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate;

19,20-dihydromutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate;

mutilin 14-(quinuclidin-3-yloxy)-acetate;

mutilin 14-(quinuclidin-3-ylsulfanyl)-acetate;

mutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate;

mutilin 14- [N-(2,2-dimethylazabicyclo[4.3.0]non-4-ylmethyl)]-aminoacetate;

mutilin 14-(quinuclidin-4-ylcarbonylamino)-acetate;

mutilin 14-[(3R,4R)-azabicyclo[2.2.1]hept-3-ylcarbonylamino]-acetate;

mutilin 14-(quinuclid-4-ylmethylsulfanyl)-acetate;

19,20-dihydromutilin 14-(quinuclidin-4-ylsulfonyl)acetate;

19,20-dihydromutilin 14-(quinclidin-4-ylsulfoxy)-acetate;

mutilin 14-{(3RS,4SR)-1-aza-bicyclo[2.2.1]hept-3-yl-sulfanyl}-acetate;

mutilin 14-(quinuclidin-3-ylidene)-acetate;

mutilin 14-[quinuclidin-3-yl]-acetate;

mutilin 14-[quinuclidin-3-ylacetoxy]-acetate;

mutilin 14-(quinuclidin-3-ylmethylsulfanyl)-acetate;

1,2-didehydromutilin 14-(quinuclidin-4-ylsulfanyl)-acetate;

2.alpha.-hydroxymutilin 14-(quinuclidin-4-ylsulfanyl)-acetate;

mutilin 14-(quinuclidin-4-yl)-acetate;

mutilin 14-(quinuclidin-4-ylmethyl)-aminoacetate;

mutilin 14-[3-(quinuclidin-4-yl)-acrylate;

mutilin 14-[3-(quinuclidin-4-yl)]-propionate;

mutilin 14-(quinuclidin-4-ylmethyloxy)-acetate;

mutilin 14-[(3R)-quinuclidin-3-ylamino]-acetate;

mutilin 14-(quinuclidin-4-yl-amino)-acetate;

mutilin 14-[(3R)-quinuclidin-3-ylamino )]-acetate;

mutilin 14-(quinuclidin-4-yl-amino)-acetate;

mutilin 14-[4-(quinuclidin-4-yl)]-butyrate;

mutilin 14-(1-azabicyclo[3,3,0]oct-4-ylmethylsulfanyl)-acetate;

mutilin 14-(1-azabicyclo[3,3,0]oct-3-ylsulfanyl)-acetate;

mutilin 14-(endo 8-methyl-8-azabicyclo[3,2,1]oct-3-ylsulfanyl)-acetate;

mutilin 14-(1-azabicyclo[4,3,0]non-4-ylsulfanyl)-acetate;

19,20-dihydromutilin 14-(1-azabicyclo[4,3,0]non-4-ylsulfanyl)-acetate;

mutilin 14-{(3S,4R)-1-azabicyclo[2.2.1]hept-3-ylmethylsulfanyl}-acetate;

mutilin 14-(quinuclidin-2-ylmethylsulfanyl)-acetate;

mutilin 14-(1-azabicyclo[2.2.1]hept-4-ylmethylsulfanyl)-acetate;

mutilin 14-{(3R,4S)-1-azabicyclo[2.2.1]hept-3-ylmethylsulfanyl}-acetate;

mutilin 14-(1-azabicyclo[3.2.1]oct-5-ylmethylsulfanyl)-acetate;

mutilin 14-(quinuclidin-4-ylmethylsulfanyl)-acetate;

mutilin 14-(8-methyl-8-azabicyclo [3.2.1]oct-3-ylmethylsulfanyl)-acetate;

mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate;

mutilin 14-[(3-(quinuclidin-4-ylsulfanyl)]-propionate;

mutilin 14-[3-(quinuclidin-4-ylmethylsulfanyl)]-propionate;

19,20-dihydromutilin 14-(8-methyl-8-azabicyclo[3.2.1]oct-3-ylmethylsulfanyl)-acetate;

mutilin 14-[4-(quinuclidin-4-ylsulfanyl)]-butyrate; and

mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate.

8. A process for preparing a compound according to claim 1 which comprises:

(a) coupling mutilin or epi-mutilin having a protected hydroxy group at position 11, with an active derivative, such as an acid chloride, of a carboxylic acid R.sup.2A --(CH.sub.2).sub.m --X--(CH.sub.2).sub.n --CH.sub.2 CO.sub.2 H , where R.sup.2A is R.sup.2 as defined in claim 1 or a group convertible thereto, and n, m, and X are as defined in claim 1, and if necessary converting the epi-mutilin to mutilin, and where necessary or desired, before or after the coupling, modifying the mutilin nucleus to introduce 2--OH; 19,20-dihydro; or 1,2-dehydro substituents; or

(b) providing a mutilin or epi-mutilin drivative having (CH.sub.2).sub.n CH.sub.2 CO as an O-acyl group at position 14, where the acyl group is substituted with R.sup.L, which is a leaving group, OH or NH, coupling the 14-O-acyl-(epi)mutilin derivative with a compound R.sup.2A (CH.sub.2).sub.m XH or an active derivative therof, and if necessary converting the epi-mutilin configuration to mutilin, and where necessary or desired, before or after the coupling, modifying the mutilin nucleus to introduce 2-OH; 19,20-dihydro; or 1,2-dehydro substituents.

9. A process for preparing a compound according to claim 8(b) in which

(a) when X is O, S or NH, R.sup.L is a leaving group and is reacted with

(i) the alcohol R.sup.2 --(CH2).sub.m --OH;

(ii) the thiol R.sup.2 --(CH.sub.2).sub.m --SH;

(iii) the amine R.sup.2 --(CH.sub.2).sub.m --NH.sub.2 ;

(b) when X is CONH, R.sup.L is amino and is reacted with the acid R.sup.2A --(CH.sub.2).sub.m --CO.sub.2 H, or an acylating agent derived therefrom;

(c) when X is CO.O, R.sup.L is hydroxy and is reacted with an acylating agent derived from the acid R.sup.2A --(CH.sub.2).sub.m --CO.sub.2 H.

10. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition according to claim 10 in the form of a spray adapted for administration to the nasal cavity.

12. A pharmaceutical composition according to claim 11 in which the spray is an aqueous spray.

13. A method of treating bacterial infection which method comprises administering an anti-bacterial effective amount of a compound of formula (IA) or (IB) according to claim 1 to a patient in need thereof.

14. A method of reducing or eliminating the nasal carriage of pathogenic organisms which method comprises administering an effective amount of a compound of formula (IA) or (IB) according to claim 1 to a patient in need thereof.

15. A method of prophylaxis of recurrent otitis media or recurrent acute bacterial sinusitis which comprises administering an effective amount of a compound of formula (IA) or (IB) according to claim 1 to a patient in need thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus